Author:
Al-Mohammed H. I.,Sulieman A.,Mayhoub Fareed H.,Salah Hassan,Lagarde Celestino,Alkhorayef M.,Aldhebaib Ali,Kappas C.,Bradley D. A.
Abstract
AbstractWorldwide, thyroid cancer accounts for some 10% of total cancer incidence, most markedly for females. Thyroid cancer radiotherapy, typically using 131I (T1/2 8.02 days; β− max energy 606 keV, branching ratio 89.9%), is widely adopted as an adjunct to surgery or to treat inoperable cancer and hyperthyroidism. With staff potentially receiving significant doses during source preparation and administration, radiation protection and safety assessment are required in ensuring practice complies with international guidelines. The present study, concerning a total of 206 patient radioiodine therapies carried out at King Faisal Specialist Hospital and Research Center over a 6-month period, seeks to evaluate patient and occupational exposures during hospitalization, measuring ambient doses and estimating radiation risk. Using calibrated survey meters, patient exposure dose-rate estimates were obtained at a distance of 30-, 100- and 300 cm from the neck region of each patient. Occupational and ambient doses were measured using calibrated thermoluminescent dosimeters. The mean and range of administered activity (AA, in MBq) for the thyroid cancer and hyperthyroidism treatment groups were 4244 ± 2021 (1669–8066), 1507.9 ± 324.1 (977.9–1836.9), respectively. The mean annual occupational doses were 1.2 mSv, that for ambient doses outside of the isolation room corridors were found to be 0.2 mSv, while ambient doses at the nursing station were below the lower limit of detection. Exposures to staff from patients being treated for thyroid cancer were less compared to hyperthyroidism patients. With a well-defined protocol, also complying with international safety requirements, occupational exposures were found to be relatively high, greater than most reported in previous studies.
Funder
Deanship of Scientific Research, King Saud University
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. SCR. Kingdom of Saudi Arabia Saudi Health Council National Health Information Center Saudi Cancer Registry. Cancer Incidence Report Saudi Arabia 2015 (2018). https://nhic.gov.sa/eServices/Documents/E%20SCR%20final%206%20NOV.pdf.accessed Nov 12, 2020.
2. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. https://doi.org/10.3322/caac.21660 (2021).
3. Hussain, F. et al. Incidence of thyroid cancer in the Kingdom of Saudi Arabia, 2000–2010. Hematol. Oncol. Stem Cell Ther. 6, 58–64 (2013).
4. Haugen, B. R. et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016).
5. Korkusuz, H., Happel, C., Koch, D. A. & Gruenwald, F. Combination of ultrasound-guided percutaneous microwave ablation and radioiodine therapy in benign thyroid disease: a 3-month follow-up study. Rofo. 188(1), 60–68 (2016).
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献